Posted by Michael Wonder on 31 Jul 2023
Fair allocation of scarce CAR T-cell therapies for relapsed/refractory multiple myeloma
31 July 2023 - The treatment landscape for relapsed/refractory multiple myeloma has undergone an immunotherapeutic breakthrough with the introduction of two commercial B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapies for patients with heavily pretreated relapsed/refractory multiple myeloma: idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti).
These therapies have led to durable responses and significantly reduced the risk of progression or death compared with alternative chemotherapies.
